These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 16244481)

  • 41. A retrospective analysis of intramuscular haloperidol and intramuscular olanzapine in the treatment of agitation in drug- and alcohol-using patients.
    MacDonald K; Wilson MP; Minassian A; Vilke GM; Perez R; Cobb P; Tallian K; Becker O; Feifel D
    Gen Hosp Psychiatry; 2010; 32(4):443-5. PubMed ID: 20633750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation.
    Baker RW; Kinon BJ; Maguire GA; Liu H; Hill AL
    J Clin Psychopharmacol; 2003 Aug; 23(4):342-8. PubMed ID: 12920409
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania.
    Tohen M; Goldberg JF; Gonzalez-Pinto Arrillaga AM; Azorin JM; Vieta E; Hardy-Bayle MC; Lawson WB; Emsley RA; Zhang F; Baker RW; Risser RC; Namjoshi MA; Evans AR; Breier A
    Arch Gen Psychiatry; 2003 Dec; 60(12):1218-26. PubMed ID: 14662554
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
    Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
    Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia.
    Sultzer DL; Gray KF; Gunay I; Berisford MA; Mahler ME
    Am J Geriatr Psychiatry; 1997; 5(1):60-9. PubMed ID: 9169246
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calming versus sedative effects of intramuscular olanzapine in agitated patients.
    Battaglia J; Lindborg SR; Alaka K; Meehan K; Wright P
    Am J Emerg Med; 2003 May; 21(3):192-8. PubMed ID: 12811711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial.
    Berk M; Brook S; Trandafir AI
    Int Clin Psychopharmacol; 1999 May; 14(3):177-80. PubMed ID: 10435771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
    Street JS; Clark WS; Gannon KS; Cummings JL; Bymaster FP; Tamura RN; Mitan SJ; Kadam DL; Sanger TM; Feldman PD; Tollefson GD; Breier A
    Arch Gen Psychiatry; 2000 Oct; 57(10):968-76. PubMed ID: 11015815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Haloperidol for agitation in dementia.
    Lonergan E; Luxenberg J; Colford J
    Cochrane Database Syst Rev; 2002; (2):CD002852. PubMed ID: 12076456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.
    Beasley CM; Tollefson G; Tran P; Satterlee W; Sanger T; Hamilton S
    Neuropsychopharmacology; 1996 Feb; 14(2):111-23. PubMed ID: 8822534
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
    Sommer OH; Aga O; Cvancarova M; Olsen IC; Selbaek G; Engedal K
    Dement Geriatr Cogn Disord; 2009; 27(2):155-63. PubMed ID: 19182483
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rescue Sedation When Treating Acute Agitation in the Emergency Department With Intramuscular Antipsychotics.
    Klein LR; Driver BE; Horton G; Scharber S; Martel ML; Cole JB
    J Emerg Med; 2019 May; 56(5):484-490. PubMed ID: 30745194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Zuclopenthixol and haloperidol/levomepromazine in the treatment of elderly patients with symptoms of aggressiveness and agitation: a double-blind, multi-centre study.
    Fuglum E; Schillinger A; Andersen JB; Belstad BE; Jensen D; Müller F; Müller KJ; Schulstad B; Elgen K
    Pharmatherapeutica; 1989; 5(5):285-91. PubMed ID: 2568639
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A naturalistic evaluation of intramuscular ziprasidone versus intramuscular olanzapine for the management of acute agitation and aggression in children and adolescents.
    Khan SS; Mican LM
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):671-7. PubMed ID: 17201611
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial.
    Mowla A; Pani A
    J Clin Psychopharmacol; 2010 Feb; 30(1):40-3. PubMed ID: 20075646
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.